## EW: Edwards Lifesciences Corporatio - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -2.3% below STRENGTH zone (3.0-6.0%); PEG 4.13 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($80.56)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 4, Bearish: 0)

**1. Edwards Lifesciences stock price target raised to $95 from $90 at Bernstein**
- Source: Investing.com | 20251208T121010 | Bullish | Relevance: 100%
-  Bernstein SocGen Group has increased its price target for Edwards Lifesciences (NYSE:EW) to $95 from $90, maintaining a Market Perform rating and citing increased confidence in the company's 2026 organic growth outlook and margin expansion. This adjustment reflects an improved price-to-earnings multiple and aligns with the company's strong financial position and recent positive analyst responses to its strategic plans. The stock is currently trading near its 52-week high, with InvestingPro data showing over 20% growth in the past year.

**2. Amundi Raises Stock Position in Edwards Lifesciences Corporation $EW**
- Source: MarketBeat | 20251206T083737 | Bullish | Relevance: 99%
-  Amundi significantly increased its stake in Edwards Lifesciences (EW) by 18.6% in Q2, valuing its holdings at $266.6 million and reflecting strong institutional investor interest with 79.46% ownership. Edwards Lifesciences exceeded quarterly earnings expectations, reporting $0.67 EPS against an estimated $0.59, and saw a revenue increase of 14.7% year-over-year to $1.55 billion. Analysts maintain a "Moderate Buy" rating with an average target price of $92.91, despite recent insider share sales, highlighting confidence in the company's financial performance and future guidance.

**3. Edwards Lifesciences (NYSE:EW) Price Target Raised to $100.00 at Royal Bank Of Canada**
- Source: MarketBeat | 20251206T145949 | Bullish | Relevance: 98%
-  Royal Bank Of Canada has increased its price target for Edwards Lifesciences (NYSE:EW) to $100.00 from $95.00, maintaining an "outperform" rating. This adjustment follows Edwards Lifesciences' strong quarterly earnings, which surpassed analyst expectations, and favorable revenue growth. The company also provided optimistic guidance for both Q4 and FY2025 earnings per share.

**4. Edwards Lifesciencesâ€™ Markowitz sells $50k in stock By Investing.com**
- Source: Investing.com India | 20251208T232816 | Somewhat-Bullish | Relevance: 98%
-  Wayne Markowitz, CVP, JAPAC at Edwards Lifesciences Corp (NYSE:EW), sold 583 shares of common stock for $50,143. This transaction occurred as the company trades near its 52-week high, with a market capitalization of approximately $49 billion. Despite this insider selling, InvestingPro data indicates aggressive share buybacks by management, and the company maintains a "GOOD" financial health score.

**5. WINTON GROUP Ltd Acquires 43,197 Shares of Edwards Lifesciences Corporation $EW**
- Source: MarketBeat | 20251208T130757 | Somewhat-Bullish | Relevance: 98%
-  WINTON GROUP Ltd significantly increased its stake in Edwards Lifesciences Corporation by buying an additional 43,197 shares, bringing its total holding to 74,078 shares valued at approximately $5.79 million. This occurred despite some insider selling by C-suite executives, including the VP and CFO. Edwards Lifesciences also reported strong quarterly earnings, beating estimates with $0.67 EPS and $1.55 billion in revenue, and received a "Moderate Buy" average analyst rating with a target price of $92.91.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 9, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-08 | Barclays | $103 | $99 | +4% |
| 2025-12-05 | Canaccord Genui | $89 | $84 | +6% |
| 2025-12-05 | Stifel | $100 | $95 | +5% |
| 2025-12-05 | UBS | $92 | $90 | +2% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-08 | Barclays | main | Overweight |
| 2025-12-05 | Canaccord Genui | main | Hold |
| 2025-12-05 | Stifel | main | Buy |
| 2025-12-05 | UBS | main | Neutral |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 4 ($0.06M) |
| Sells | 3 ($0.90M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 51.3% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 8 / 2 |

**Top Holders:**
- Vanguard Group Inc: 12.1% (+0.5%)
- Blackrock Inc.: 9.4% (-2.4%)
- JPMORGAN CHASE & CO: 8.6% (+87.2%)
- State Street Corpora: 4.4% (-0.1%)
- Wellington Managemen: 3.6% (+4.9%)

### Key Risks

1. Valuation stretched: PEG 4.1x requires aggressive growth execution.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 9 raises (avg +4%) could attract flows.
- AI/machine learning initiatives could drive multiple expansion if executed.

### Fundamentals

PEG ratio 4.13 signals overvaluation risk, limited margin of safety. Forward P/E 29.4x stretched relative to 11% growth. Quality metrics strong (margin 23%). Balance sheet: strong liquidity (4.0x), low leverage (D/E 0.30). Institutional flow bullish (8 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $49.5B |
| Beta | 0.97 |
| 52W Range | $65.94 - $87.89 |
| Short Interest | 1.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 4.13 |
| Forward P/E | 29.4 |
| Current P/E | 32.6 |
| YoY Growth | 11.1% |
| EPS Direction | STABLE |

### Technicals

MRS_10 improving modestly (+0.9% over 5 days). Below STRENGTH zone by 5.3pp (needs >3.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.10x) but short-term weakness (below SMA20). RSI neutral at 51.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -2.34% (CS: 31) | Weak |
| RSI_14 | 51.2 | Neutral |
| MACD Histogram | -0.36 | Bearish |
| vs SMA20 | 0.988x | Below |
| vs SMA50 | 1.042x | Above |
| vs SMA200 | 1.098x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $84.32
- **Stop Loss:** $80.56 (4.5% risk)
- **Target:** $88.08 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 132
- **Position Value:** $11,130.24
- **Portfolio %:** 11.13%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

### Earnings

**Next:** 2026-02-11 (Est: $0.62)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.59 | $0.67 | +12.6% |
| 2025Q2 | $0.62 | $0.67 | +7.6% |
| 2025Q1 | $0.60 | $0.64 | +7.5% |
| 2024Q4 | $0.55 | $0.59 | +6.4% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*